A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Astegolimab in Patients with Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)

1. Annualized rate of moderate and severe COPD exacerbations over the 52-week treatment period

1.Time to first moderate or severe COPD exacerbation during the 52-week treatment period, 2. Absolute change from baseline in HRQoL at Week 52, as assessed through the St. George's Respiratory Questionnaire-COPD (SGRQ-C) total score, 3. Proportion of patients with improvement in HRQoL, defined as a decrease from baseline of >/=4 points in SGRQ-C total score, at Week 52, 4. Absolute change from baseline in post-bronchodilator FEV1 (liters) at Week 52, 5. Absolute change from baseline in Evaluating Respiratory Symptoms in COPD (E-RS:COPD) total score at Week 52, 6. Annualized rate of severe COPD exacerbations over the 52-week treatment period, 7. Absolute change from baseline in five-repetition sit-to-stand test (5STS) time (seconds) at Week 52, 8. Incidence and severity of adverse events, 9. Serum concentration of astegolimab at specified timepoints, 10. Prevalence of anti-drug antibodies (ADAs) at baseline and incidence of ADAs during the study

No related papers found yet.

None listed

Belgium, Bulgaria, Czechia, Denmark, France, Germany, Netherlands, Poland, Romania, Spain, Sweden